



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Bell

Serial No.:

10/047,608

Filed:

January 14, 2002

For:

METHODS OF PROPHYLAXIS AGAINST LARGE

MYOCARDIAL INFRACTIONS

## **CERTIFICATE OF MAILING**

Date of Deposit: January 7, 2003

I hereby certify that the following:

[x] This Certificate of Mailing

[x] Information Disclosure Statement

[x] 1449 Form with Cited Art

[x] Return Postcard

are being deposited with the United States Postal Service first-class mail on the Date of Deposit indicated above in an envelope addressed to the ATTN: Assistant Commissioner of Patents, Washington, D.C. 20231.

Lori Rooney

Mark Farber C/O Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire, CT 06410





Docket:

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Bell

Serial No:

10/047,608

Examiner: U

Unassigned

59 US

Filed:

January 14, 2002

Group Art Unit: 1614

For:

METHOD OF PROPHYLAXIS AGAINST LARGE MYOCARDIAL INFRACTIONS

Assistant Commissioner of Patents Washington, D.C. 20231

## INFORMATION DISCLOSURE STATEMENT

In accordance with Applicant's duty of disclosure under 37 C.F.R §1.56, Applicants submit the enclosed reference for the Examiner's consideration.

It is respectfully requested that the reference(s) submitted with Form PTO-1449 be considered during Examination of the above-identified application and made of record therein. A copy of the reference(s) is/are enclosed. This submission is believed to be in compliance with 37 C.F.R. §1.97 and 37 C.F.R. §1.98.

The citation of the listed item(s) is not a representation that it constitutes a complete or exhaustive listing of prior art or that it constitutes prior art. The item(s) listed is/are submitted in good faith, but is/are not intended to substitute for the Examiner's search. It is hoped, however, that in addition to apprising the Examiner, it will assist the Examiner in identifying fields of search and in making as full and complete a search as possible.

The filing of this information disclosure statement is not an admission that the information cited herein is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

- ( ) This information disclosure statement is being filed within three
- (3) months of the filing date of this application.
- () This information disclosure statement is being filed within three (3) months of the date of entry of the national stage as set forth in
- 37 C.F.R.§ 1.491 in an international application.
- $(\mathbf{x})$  To the best of Applicant(s) knowledge, this information disclosure statement is being filed before the date of mailing of a first Office Action in connection with this case.
- ( ) Enclosed is a certificate under 37 C.F.R. §1.97 (e)(i).

- (.) Please charge the petition fee of \$130.00 required under 37 C.F.R. §1.17 (i)(1) to Deposit Account No. 01-0483.
- () As set forth in 37 C.F.R.  $\S1.97$  (c), to the best of Applicant(s) knowledge, this information disclosure statement is being filed before either the mailing of a final action under 37 C.F.R. $\S1.113$  or the mailing of a notice of allowance under 37 C.F.R.  $\S1.113$ , and is accompanied by the  $\S220.00$  fee as provided for in 37 C.F.R.  $\S1.17$ (p).
- ( ) Please charge the \$240.00 fee required by 37 C.F.R.  $\S1.17(p)$  to Deposit Account No. 01-0483.
- (x) Please charge any deficiency as well as any other fee(s) which may become due under 37 C.F.R. §1.16 and/or 37 C.F.R. §1.17 at any time during the pendency of this application, or credit any overpayment of such fee(s) to Deposit Account 01-0483. Also, in the event any extensions of time for responding are required for the pending application(s), please treat this paper as a petition to extend time as required and charge Deposit Account No. 01-0483 therefor. TWO COPIES OF THIS SHEET ARE ENCLOSED.

Early and favorable consideration of the case is respectfully requested.

Dated:

Mark Farber

Registration No. 34,159 Attorney for Applicants

Mark Farber C/O Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire, CT 06410 (203) 271-8319

Form P	TO-	14	49		Ţ	J.S	. ]	DEP.	ARTMENT OF	F P	ATTY. DOCKE	T NO.	<del></del>			SERIAL	NO.
COMMERCE PATENT AND TRADEMARK OFFICE									MARK OFFIC	E	59 U	S			10	/047,60	18
INFORMATION DISCLOSURE STATEMENT BY APPLICANT															10	,047,00	, 0
			:		s.	<b>:</b> .	•	•									
(Use	ser	rer	芒	-s\	ie e	ts	1:	E n	ecessary)	7	PPLICANT						
	/·	'A		_		37				A	Bell						
	(0	)		O ST	<b>P</b>	37				F	ILING DATE				GR	OUP Art	Unit:
		_1	1			ğ					Janua	ary 14, 2	2002		16	14	
		۰	<b>.</b>	. 4	, No					וו כ דות	ENT DOCUMEN	m					
EXAMINER		7	TEMP & TRAD							U.S. PATENT DOCUMENT						FILI	NG DATE
INITIALS	DOCUMENT I NUMBER								DATE	NAME			CI	LASS	SUBCLA	SS	IF
		4		8	5	4	5		1/15/91	Sunshine	et al.					APPRO	OPRIATE
	↓	5	_	3		-	<u> </u>		6/03/97	Sims et a					RE		
	$\vdash$	6	3	5	5	2	4	5	3/12/02	Evans et	_al				12		
	-	-	<u> </u>	$\vdash$		┨┤		$\vdash$				<del></del>			JAN	<b>&gt;</b> /V	EA
	1			$\dashv$		H		$\vdash$					<del>-                                     </del>	FOI	, -7//	7 9 20	<u> </u>
						П		H			.,,			-U/	CENTA	<u> </u>	<del></del>
															-11/2/	16000	
	ļ	┝		$\Box$		$\vdash \vdash$		4								7 1600/28	100
	<del> </del>		-	$\dashv$		$\vdash$	-	+			<del></del>					_	
						H		+				<del></del>					
									FC	REIGN PAT	TENT DOCUME	NTS			I		·
		Т								Τ				<del></del>		TRANSI	LATION
	DOCUMENT								DATE	COUNTRY			CLASS	SU	BCLASS		21111011
	NUMBER						ĸ								YES	T NO	
			9 .	5 2	2 !	5 5	5 4	1 0	9/28/95	WO		<del></del>		<del> </del> -		165	NO
		4	4	┵	4		Į.	$\perp$									
		+	+	- -	+	-	╄										
	-	$\top$	+	+	╁	╁	+	+-		<del></del>							-
		0	TH	ER	DC	CUI	MEI	NTS	(Includin	g Author,	Title, Da	te, Perti	nent P	age	s, Etc	.)	
<del></del>		_										,			<del></del>	·	
	Abdelmeguid et al., Circulation, 1995:91:2733-2741  Buerke et al., Journal of Immunology, 2001: Vol 6, No 9: 5375-5380  Calliff et al, J.AmColl Cardiol, 1998:31:241-251										5380						
												<del> </del>					
	Fitch et al., Circulation, 1999:Vol. 100, No. 25;2502-2504												·				
		$\vdash$							irculation,			/					
		+	1	/len	aso	che	a I .	nna	AMA, 1997:2	2//:461-466	ry, 2001:Vol	6 No 7	2 - 62260	022			
		$\top$	1	Γho	mas	s et	t a	11.,	Molecular 1	[mmunology	, 1996, Vol.	33, No. 17	/18 13:	- 522 89 - 1	401		
	Thomas et al., Molecular Immunology, 1996, Vol.33, No.17/18, Wurzner et al., Complement Inflamm., 8:328-340, 1991																<del></del>
		L	+									-					
		+	+					-									
		$\vdash$	+														
EXAMINER	2						-			DATE CON	NSIDERED				<u> </u>		
EXAMINER		Tni	ti	аl	i 1	F C	<u>i</u> +	ati	on conside	ared what	her or not						
ous; Dra	w.	ıır.	ιe	cn:	roı	ıgn	C.	ıta	tion if no	ot in conf	ormance an	citation d not com	n 15 17 nsidere	ı co	ntorma: Includ	nce wit	n MPEP
this for	m v	wit	h	ne	xt	co	mm	uni	cation to	applicant	· · · · · · · · · · · · · · · · · · ·					- COPY	<b>-</b>